Siemens CEO Peter Löscher ousted amid revenue struggle

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here each Friday.

Siemens CEO Peter Löscher ousted amid revenue struggle

Siemens ($SI) pulled the plug on CEO Peter Löscher as the company revealed a reorganization of this year's fiscal goals. The German healthcare med tech business said it no longer expects to meet the 12% profit margin it initially proclaimed for fiscal 2013, leading to a 7% drop in shares. Löscher's spot at the top will go to Joe Kaeser, Siemens' former CFO, who will now be expected to mop up the struggling revenue base. Story

Peter Löscher, Siemens
Löscher will be replaced by CFO Joe Kaeser.

Joseph Bolen, Moderna
Bolen will lead Moderna's R&D.

Biotech

> Moderna Therapeutics brought on Joseph Bolen as the company's president of research and development. Bolen, the former chief scientific officer and global head of oncology research at Millennium, began his career at the National Institutes of Health. Release

Advanced Prenatal Therapeutics has appointed its first scientific adviser, Dr. Nihar Nayak. Nayak is an associate professor of Obstetrics and Gynecology and the director of Translational Research in the Division of Maternal-Fetal Medicine at Stanford University School of Medicine. Release

Clinverse has hired Bud Owen as chief financial officer and Tony Click as chief technology officer. Release

Genesis Biopharma has appointed Sanford J. Hillsberg and Dr. Jay Venkatesan to its board of directors. Genesis also announced that Paul Kessler and David Voyticky have turned in their resignations as directors. Release

Dr. Raymond L. Woosley has been appointed to ARCA biopharma's ($ABIO) board of directors. Woosley is the president and chairman of the board of the Arizona Center for Education and Research on Therapeutics. Release

Gil Yosipovitch and Praveen Anand joined the scientific advisory board at Creabilis. Article

Insmed ($INSM) appointed Christine Pellizzari as general counsel and corporate secretary. Pellizzari was most recently executive vice president, general counsel and corporate secretary at Aegerion Pharmaceuticals ($AEGR). Release

Chris Gowland joined Aesica as the company's newly added chief operating officer. Release

Pharma

Two new members have been appointed to Sanofi's ($SNY) executive committee. Carsten Hellmann joins Sanofi from Chr. Hansen Holding A/S and will take the position of executive vice president of Merial, the company's animal health division, replacing Jose Barella. Dr. David Meeker, currently CEO of Genzyme and a member of the Global Leadership Team, will join the executive committee as executive vice president, Genzyme. Release

Robert P. Roche Jr. has joined Antares Pharma's ($ATRS) board of directors. Roche previously led commercial operations at Cephalon and was executive vice president at Worldwide Pharmaceutical Operations. Release

Medical Devices

Horizon Discovery has appointed Dr. Ian Gilham to its board of directors. Gilham has previously been CEO of Axis-Shield plc and vice president, Pharmacogenetics and Diagnostics at GlaxoSmithKline ($GSK). Release

CRO

Advanced Clinical has added Cheryle Evans to its leadership team as vice president, Clinical Operations. Prior to joining Advanced, Evans served as vice president, Clinical Operations for North America with a top 5 CRO. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.